Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
Date:11/1/2010

ndidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking StatementsCertain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Kidney Augment and the Neo-Urinary Conduit; and (ii) expectations regarding ongoing and planned preclinical studies and clinical trials. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to obtain the capital it needs to develop its product candidates or continue as a going concern; (ii) the Company will be able to successfully enroll patients in its clinical trials, including its  Phase I clinical trial for the Neo-Urinary Conduit; (iii) patients enrolled in the Company's clinical trials will not experience adverse events related to the Company's product candidates, which could delay clinical trials or cause the Company to terminate the development of a product candidate; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further dev
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the second ... "The second quarter of 2014 ... Doug Murphy-Chutorian , M.D., chief executive officer of ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... , May 20 As the medical device industry gathers ... of Sales Content Management software, offers medical device companies a solution to ... , , ... Sciences at Prolifiq, will lead the workshop "Sales-Friendly Compliant Content Communication: How ...
... NEW YORK , May 19 ... stage, specialty pharmaceutical and medical device company focused on ... Oncology (ASCO) has accepted an oral presentation of Delcath,s ... (PHP-mel) to the best alternative care for patients with hepatic ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 2Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 3
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 ... China Gel Permeation Chromatography Industry” is a ... Global and China Gel Permeation Chromatography market. ... information, including Gel Permeation Chromatography definition, classification, ... as industry overview. This research covers the ...
(Date:7/25/2014)... Los Angeles, CA (PRWEB) July 25, 2014 ... to talk about, and eager to reverse the symptoms associated ... health in the media at large, a new case ... the real benefits of testosterone therapy using bioidentical ... Jason, a 38-year-old father from Seattle who found himself beginning ...
(Date:7/25/2014)... 2014 American motor vehicle owners who ... can pay higher premiums for vehicle insurance on average. ... network to provide SR22 insurance for high risk motorists ... different coverage network of local agencies providing direct price ... platform now publicly available for any car owner to ...
(Date:7/25/2014)... As reported by the Statesman Journal in ... (7/20), police in Salem, MA as well as several ... recent heroin epidemic that has taken many lives during the ... overdose case in which police were able to make two ... By pretending to be the victim and claiming to want ...
Breaking Medicine News(10 mins):Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Multiple States Crack Down on Heroin Epidemic 2
... Calif., Dec. 8 Anesiva, Inc. (Nasdaq: ANSV ) ... with Arcion Therapeutics, Inc. ("Arcion") during its December 3, 2009 ... also approved a one-for-forty reverse stock split, which will be ... Closure of the merger remains contingent upon Anesiva achieving multiple ...
... PROVERI, Inc. is pleased to announce that it ... Venture Summit Top Innovator award by youngStartup Ventures. The list ... in innovation for the Technology, Life Sciences and Clean-tech sectors. , ... Executive Officer of PROVERI, Inc., will present the company at the ...
... , LONDON, Dec. 8 Over the past ... regarding the investment in healthcare information technology. Today, hospitals are ... in the Healthcare IT industry are in the process of ... an innovative product to market. At the same time, the ...
... , ANN ARBOR, Mich., Dec. ... revolutionary bench-top flow cytometer systems, today announced the 2009 recipients ... a free Accuri C6 Flow Cytometer® System each year to ... in Europe, who propose innovative uses of flow cytometry. ...
... ... 6.4 has just arrived. It offers new features for effectively working with Microsoft Office ... ... fanfare with interface updates and a powerful 64-bit capability. To date, InfoZoom has ...
... , LONDON, Dec. 8 Healthcare in ... of resources as the region,s working population is far lower in ... of new schemes in healthcare that would enable Europe to deal ... Information and Communication Technology (ICT) in healthcare is evident from the ...
Cached Medicine News:Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: